Last checked at 29 Jul 2015 17:41
Issued: 29 July 2015, London, U.K. |
GlaxoSmithKline Capital plc |
Results announcement and interim management report for the half year ended 30 June 2015 |
Performance GlaxoSmithKline Capital plc (the "Company"), a wholly owned indirect subsidiary of GlaxoSmithKline plc, issues US and Euro Medium Term Notes and provides financing and financial services to fellow subsidiaries of GlaxoSmithKline plc and its subsidiaries (the "Group"). During the period the Company made a profit on ordinary activities after taxation of £4,061,000 (2014: £2,852,000).
The Company repaid a three year $1 billion fixed rate bond which matured in May 2015, reducing trade payables due within one year to £1,283,774,000 (2014: £2,010,305,000). The Company has not issued any further US and Euro Medium Term Notes during the six months to 30 June 2015.
The Company seeks to denominate borrowings in the currencies of its principal assets and cash flows. These are primarily denominated in Euros, US Dollars and Sterling.
The policy on interest rate risk management limits the amount of floating interest payments to a prescribed percentage of trading profit.
After making certain enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing this document, due to ongoing support from the intermediate parent undertaking, GlaxoSmithKline Finance plc. |
Outlook The Directors are of the opinion that the current level of activity and the period end financial position are satisfactory and will remain so in the foreseeable future. |
GlaxoSmithKline Capital plc, 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom. Registered in England and Wales. Registered number: 2258699 |
GlaxoSmithKline Capital plc |
Income Statement |
Six months ended 30 June 2015 |
Notes | Period ended30 June 2015£'000 | Period ended30 June 2014£'000 | |||||
Operating (loss)/profit | (353) | 16 | |||||
Finance income | 2 | 205,468 | 200,580 | ||||
Finance expense | 2 | (199,964) | (196,899) | ||||
Net finance income | 5,504 | 3,681 | |||||
Profit on ordinary activities before interest and taxation | 5,151 | 3,697 | |||||
Income tax expense on ordinary activities | 1 | (1,090) | (845) | ||||
Profit for the period | 4,061 | 2,852 | |||||
Statement of Comprehensive Income |
Six months ended 30 June 2015 |
Period ended30 June 2015£'000 | Period ended30 June 2014£0'000 | |||
Profit for the period | 4,061 | 2,852 | ||
Other comprehensive income: Items that may be reclassified to income statement: | ||||
Reclassification of cash flow hedges to income statement | 477 | 298 | ||
Other comprehensive income for the period | 477 | 298 | ||
Total comprehensive income for the period | 4,538 | 3,150 | ||
GlaxoSmithKline Capital plc |
Statement of Financial Position As at 30 June 2015 |
Notes | 30 June 2015£'000 | 31 December 2014£'000 | |||
Trade and other receivables: amounts falling due within one year | 3 | 1,347,538 | 2,066,389 | ||
Trade and other receivables: amounts falling due after one year | 3 | 9,699,572 | 10,008,530 | ||
Trade and other receivables | 11,047,110 | 12,074,919 | |||
Cash and cash equivalents | 3 | 3 | |||
Current assets | 11,047,113 | 12,074,922 | |||
Trade and other payables: amounts falling due within one year | 4 | (1,283,774) | (2,010,305) | ||
Net current assets | 9,763,339 | 10,064,617 | |||
Trade and other payables: amounts falling due after more than one year | 4 | (9,748,377) | (10,054,193) | ||
Net assets | 14,962 | 10,424 | |||
Equity | |||||
Called up share capital | 100 | 100 | |||
Retained earnings | 24,820 | 20,759 | |||
Other reserves | (9,958) | (10,435) | |||
Total equity | 14,962 | 10,424 | |||
GlaxoSmithKline Capital plc |
Statement of changes in equity |
Called up sharecapital£'000 | Retainedearnings£'000 | Other reserves£'000 | Total equity£'000 | ||||
At 1 January 2014 | 100 | 14,025 | (10,895) | 3,230 | |||
Profit for the period | - | 2,852 | - | 2,852 | |||
Other comprehensive income for the period | - | - | 298 | 298 | |||
At 30 June 2014 | 100 | 16,877 | (10,597) | 6,380 | |||
Share capital£'000 | Retainedearnings£'000 | Other reserves£'000 | Total equity£'000 | ||||
At 1 January 2015 | 100 | 20,759 | (10,435) | 10,424 | |||
Profit for the period | - | 4,061 | - | 4,061 | |||
Other comprehensive income for the period | - | - | 477 | 477 | |||
At 30 June 2015 | 100 | 24,820 | (9,958) | 14,962 | |||
GlaxoSmithKline Capital plc |
Cash flow statement Six months ended 30 June 2015 |
2015£'000 | 2014£'000 | ||
Net cash generated from operations | (7) | 398 | |
Taxation paid | (54) | (22) | |
Net cash (outflow)/inflow from operating activities | (61) | 376 | |
Cash flow from investing activities | |||
Interest received | 182,669 | 181,861 | |
Net cash inflow from investing activities | 182,669 | 181,861 | |
Cash flow from financing activities | |||
Interest paid | (175,706) | (175,165) | |
Repayment of short-term loans | (648,232) | - | |
Increase in short term loans | 644,966 | - | |
Decrease in loans with Group undertakings | (3,636) | (7,072) | |
Net cash outflow from financing activities | (182,608) | (182,237) | |
Decrease/(increase) in cash in the period | - | - | |
Cash at beginning of period | 3 | 4 | |
(Decrease)/increase in cash | - | - | |
Cash at end of period | 3 | 4 | |
GlaxoSmithKline Capital plc |
Accounting presentation and policies
This unaudited Results Announcement containing condensed financial information for the six months ended30 June 2015 is prepared in accordance with Financial Reporting Standard 104 "Interim Financial Reporting" using the recognition and measurement requirements of Financial Reporting Standard 101 "Reduced Disclosure Framework" and in accordance with the Listing Rules of the UK Listing Authority.
First time application of FRS 100, FRS 101 and FRS 104
Effective from 1 January 2015, the company has adopted FRS 100 "Application of Financial Reporting Requirements", FRS 101 "Reduced Disclosure Framework" and FRS 104 "Interim Financial Reporting". In previous years the financial statements and interim results announcements were prepared in accordance with applicable UK accounting standards and pronouncements on interim reporting issued by the Accounting Standards Board (ASB).
This change in the basis of preparation has not materially altered the recognition and measurement requirements previously applied in accordance with applicable accounting standards. Consequently the principal accounting policies set out in the Company's audited Financial Statements 2014 are unchanged and have been consistently applied in the preparation of this Results Announcement.
This Results Announcement does not constitute statutory accounts of the Company within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The Statement of Financial Position as at 31 December 2014 has been derived from the full accounts published in the Financial Statements 2014, which have been delivered to the Registrar of Companies and on which the report of the independent auditors was unqualified and did not contain a statement under section 498 of the Companies Act 2006.
Related party transactions
The Company's significant related parties are other members of the Group. Advantage has been taken of the exemption afforded by FRS 101 "Reduced Disclosure Framework" not to disclose any related party transactions with other wholly owned subsidiaries of the Group. There are no other related party transactions.
Principal risks and uncertainties
The Directors of GlaxoSmithKline plc manage the risks of the Group at a group level, rather than at an individual business unit level.
For this reason, the Company's Directors believe that a discussion of the Group's risks would not be appropriate for an understanding of the development, performance or position of the Company's business.
The principal risks and uncertainties of the Group, which include those of the Company, are discussed in the Group's 2014 Annual Report and Second Quarter 2015 Results Announcement which do not form part of this report.
In addition to the Financial Risk Management disclosed in the Treasury Policy Note of the Company's Director's Report and Financial Statements for the year ended 31 December 2014, at a Company level, the principal risks and uncertainties relevant to the Group and the Company's business and financial condition and results would include risks from Global and Political Economic Conditions, Reliance on Information Technology, and the potential impact of new or revised Accounting Standards. |
GlaxoSmithKline Capital plc |
Reliance on Information Technology
The Company is increasingly dependent on information technology systems, including internet-based systems, for internal communication as well as communication with financial counterparties. Any significant disruption of these systems, whether due to computer viruses or other outside incursions, could materially and adversely affect the Company's operations.
Impact of New or Revised Accounting Standards
New or revised accounting standards, rules and interpretations circulated from time to time by the standard setting board could result in changes to the recognition of income and expense that may adversely impact the Company's reported financial results. The Company believes that it complies with the appropriate regulatory requirements concerning their financial statements and disclosures. |
Directors' responsibility statement
The Board of Directors approved this document on 29 July 2015.
The Directors confirm that to the best of their knowledge this unaudited condensed financial information for the six months ended 30 June 2015 has been prepared in accordance with Financial Reporting Standard 104 "Interim Financial Reporting" and that the interim management report herein includes a true and fair view of the information required by Disclosure and Transparency Rules (DTR) 4.2.7.
The Directors of GlaxoSmithKline Capital plc are Edinburgh Pharmaceutical Industries Limited, Glaxo Group Limited and Simon Dingemans.
| |
By order of the Board Paul Blackburn on behalf of Glaxo Group Limited (Corporate Director) | |
29 July 2015 | |
Internet This Announcement and other information about the GSK Group are available on the website at: http://www.gsk.com. |
GlaxoSmithKline Capital plc |
Notes to the Financial Statements For the six months ended 30 June 2015 |
1 | Taxation | 30 June 2015£'000 | 30 June 2014£'000 | |||
Tax charge | 1,090 | 845 | ||||
Tax rate | 20.25% | 21.50% |
The effective tax rate is based on the anticipated charge for taxation for the year to 31 December 2015. |
2 | Finance income and expense | Period ended30 June 2015£'000 | Period ended30 June 2014£'000 | |||
Interest income arising from: | ||||||
On loans with Group undertakings | 205,468 | 200,580 | ||||
Interest expense arising on: | ||||||
Cash flow hedge recycling from equity | (477) | (298) | ||||
On US Medium Term Notes and European Medium Term Notes | (193,351) | (191,590) | ||||
Financial liabilities at amortised cost | (6,136) | (5,011) | ||||
(199,964) | (196,899) | |||||
5,504 | 3,681 |
3 | Trade and other receivables | 30 June 2015£'000 | 31 December 2014£'000 | |||
Amounts due within one year | ||||||
Amounts owed by Group undertakings - loans | 1,192,495 | 1,934,347 | ||||
Amounts owed by Group undertakings - current account | 155,043 | 132,042 | ||||
1,347,538 | 2,066,389 | |||||
Amounts due after one year | ||||||
Amounts owed by Group undertakings - loans | 9,696,836 | 10,005,834 | ||||
Deferred tax | 2,736 | 2,696 | ||||
9,699,572 | 10,008,530 | |||||
11,047,110 | 12,074,919 | |||||
GlaxoSmithKline Capital plc |
Notes to the Financial Statements For the six months ended 30 June 2015 |
4 | Trade and other payables | 30 June 2015£'000 | 31 December 2014£'000 | |||
Amounts falling due within one year | ||||||
Amounts owed to Group undertakings - current accounts | 1,737 | 1,764 | ||||
Corporation Tax | 2,880 | 1,750 | ||||
Accruals and deferred income | 144,405 | 126,759 | ||||
US Medium Term Notes | - | 640,661 | ||||
Euro Medium Term Notes | 1,134,752 | 1,239,371 | ||||
1,283,774 | 2,010,305 | |||||
Amounts due after one year | ||||||
US Medium Term Notes | 2,534,185 | 2,548,745 | ||||
Euro Medium Term Notes | 7,214,192 | 7,505,448 | ||||
9,748,377 | 10,054,193 | |||||
11,032,151 | 12,064,498 | |||||
Amounts owed to Group undertakings are unsecured and repayable on demand. | |
The corporation tax creditor contains amounts which will be paid to fellow Group companies. | |
Accruals and deferred income relates to accrued interest payable on US Medium Term Notes and Euro Medium Term Notes. | |
The Company repaid the three year $1 billion US Medium Term Note (£648.2 million) that matured on8 May 2015. Debt is unsecured and there are no debt covenants in relation thereto. |
5 | Financial instruments and related disclosures |
There are no material differences between the carrying value of the Company's other financial assets and liabilities and their estimated fair value, with the exception of Bonds, for which the carrying values and fair values are set out in the table below. |
30 June 2015 | 30 June 2015 | 31 December 2014 | 31 December 2014 | |||||
Carrying value£'000 | Fair value£'000 | Carrying value£'000 | Fair value£'000 | |||||
Bonds designated | 3,775,939 | 3,958,000 | 4,124,434 | 4,349,295 | ||||
Other bonds | 7,107,190 | 8,075,028 | 7,809,791 | 9,037,226 | ||||
10,883,129 | 12,033,028 | 11,934,225 | 13,386,521 | |||||